| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2015069110 |
| Title |
Multiple D2 A(Nta)Gonists/H3 Antagonists for Treatment of Cns-Related Disorders. |
| Abstract |
The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic effects, pharmaceutical compositions thereof, and methods of using them for application in the prophylaxis or treatment of CNS disorders. |
| Applicant(s) |
Aapa Bv |
| Representative Drug(s) |
D0RP1J |
Drug Info
|
EC50 = 0.9 nM; IC50 = 0.05 nM |
Click to Show More |
[1] |
|
2
|
D0D5AH
|
Drug Info
|
EC50 = 1.1 nM; IC50 = 0.08 nM
|
[1] |
|
3
|
D0SO4O
|
Drug Info
|
EC50 = 0.1 nM; IC50 = 0.3 nM
|
[1] |
|
4
|
D0BZ0N
|
Drug Info
|
EC50 > 1000 nM; IC50 = 22 nM
|
[1] |
|
5
|
D0N8CU
|
Drug Info
|
EC50 >= 100 nM; IC50 = 54 nM
|
[1] |
|
6
|
D05KKZ
|
Drug Info
|
EC50 >= 1000 nM; IC50 >= 100 nM
|
[1] |
| Patent ID |
WO2012176066 |
| Title |
Deuterated 1-Piperazino-3-Phenyl Indanes for Treatment of Schizophrenia. |
| Abstract |
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds. |
| Applicant(s) |
H. Lundbeck A / S |
